FibroGen Executives Depart Amid U.S. Operations Overhaul
Company Announcements

FibroGen Executives Depart Amid U.S. Operations Overhaul

Don't Miss out on Research Tools:

The latest update is out from FibroGen ( (FGEN) ).

FibroGen, Inc. is streamlining its U.S. operations with a significant cost reduction strategy, leading to the termination of two top executives, CFO Juan Graham and CMO Deyaa Adib, M.D. The executives will stay on through transition periods until their respective departure dates in December 2024 and November 2024. The company recognizes their contributions and clarifies that their departures are not due to any disagreements.

See more data about FGEN stock on TipRanks’ Stock Analysis page.

Related Articles
TipRanks Auto-Generated NewsdeskFibroGen Reports Strong Q3 Growth and Future Plans
Ryan AdistFGEN Upcoming Earnings Report: What to Expect?
TheFlyDisc Medicine appoints Kaushik as Chief Technical Officer
Looking for investment ideas? Subscribe to our Smart Investor newsletter for weekly expert stock picks!
Get real-time notifications on news & analysis, curated for your stock watchlist. Download the TipRanks app today! Get the App